Oric Pharmaceuticals Inc.(ORIC),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ORIC Oric Pharmaceuticals Inc.

Not Yet Opened 08-06 16:00:00 EDT

12.93

+0.00

0.00%

盘后12.93

+0.000.00%

19:34 EDT

High13.19	Low12.74	Vol887.67K
Open13.01	D1 Closing12.93	Amplitude3.52%
Mkt Cap1.34B	Tradable Cap1.07B	Total Shares103.52M
T/O11.47M	T/O Rate1.07%	Tradable Shares82.72M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ORIC","market":"US","secType":"STK","nameCN":"Oric Pharmaceuticals Inc.","latestPrice":12.93,"timestamp":1786046400000,"preClose":12.93,"halted":0,"volume":887665,"hourTrading":{"tag":"盘后","latestPrice":12.93,"preClose":12.93,"latestTime":"19:34 EDT","volume":30793,"amount":398129.851,"timestamp":1786059248266,"change":0,"changeRate":0,"amplitude":0.000773},"delay":0,"changeRate":0,"floatShares":82717200,"shares":103517562,"eps":-1.351255,"marketStatus":"Not Yet Opened","change":0,"latestTime":"08-06 16:00:00 EDT","open":13.005,"high":13.19,"low":12.735,"amount":11466970.978785,"amplitude":0.035189,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.351255,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1786089600000},"marketStatusCode":0,"adr":0,"listingDate":1587700800000,"exchange":"NASDAQ","adjPreClose":12.93,"preHourTrading":{"tag":"盘前","latestPrice":12.9532,"preClose":12.93,"latestTime":"09:28 EDT","volume":1539,"amount":19812.773583,"timestamp":1786022935103,"change":0.0232,"changeRate":0.001794,"amplitude":0.090487},"postHourTrading":{"tag":"盘后","latestPrice":12.93,"preClose":12.93,"latestTime":"19:34 EDT","volume":30793,"amount":398129.851,"timestamp":1786059248266,"change":0,"changeRate":0,"amplitude":0.000773},"volumeRatio":0.347936,"impliedVol":0.4106,"impliedVolPercentile":0.0518},"requestUrl":"/m/hq/s/ORIC/tweets","defaultTab":"tweets","newsList":[{"id":"2656155087","title":"Evercore ISI Keeps Their Buy Rating on Oric Pharmaceuticals (ORIC)","url":"https://stock-news.laohu8.com/highlight/detail?id=2656155087","media":"TIPRANKS","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656155087?lang=en_us&edition=fundamental","pubTime":"2026-08-04 23:29","pubTimestamp":1785857348,"startTime":"0","endTime":"0","summary":"In a report released today, Cory Kasimov from Evercore ISI maintained a Buy rating on Oric Pharmaceuticals, with a price target of $25.00. Kasimov ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/evercore-isi-keeps-their-buy-rating-on-oric-pharmaceuticals-oric-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/evercore-isi-keeps-their-buy-rating-on-oric-pharmaceuticals-oric-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ORIC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656554627","title":"Analysts Offer Insights on Healthcare Companies: Oric Pharmaceuticals (ORIC), ClearPoint Neuro (CLPT) and Keros Therapeutics (KROS)","url":"https://stock-news.laohu8.com/highlight/detail?id=2656554627","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656554627?lang=en_us&edition=fundamental","pubTime":"2026-08-04 21:50","pubTimestamp":1785851432,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Oric Pharmaceuticals (ORIC), ClearPoint Neuro (CLPT)...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-oric-pharmaceuticals-oric-clearpoint-neuro-clpt-and-keros-therapeutics-kros-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-oric-pharmaceuticals-oric-clearpoint-neuro-clpt-and-keros-therapeutics-kros-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0029874061.USD","XLV","BK4082","KROS","BK4581","ORIC","XBI","LABU","BK4585","LU0128526141.USD","BK4139","BK4588","CLPT","HCSG","BK4137"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656355120","title":"ORIC Pharmaceuticals: Buy Rating Reaffirmed with Unchanged $25 Price Target on Multiple Oncology Catalysts and mCRPC Upside","url":"https://stock-news.laohu8.com/highlight/detail?id=2656355120","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656355120?lang=en_us&edition=fundamental","pubTime":"2026-08-04 21:40","pubTimestamp":1785850801,"startTime":"0","endTime":"0","summary":"In a report released today, Boris Peaker from JonesTrading maintained a Buy rating on Oric Pharmaceuticals, with a price target of $25.00. Boris Pe...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/oric-pharmaceuticals-buy-rating-reaffirmed-with-unchanged-25-price-target-on-multiple-oncology-catalysts-and-mcrpc-upside-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/oric-pharmaceuticals-buy-rating-reaffirmed-with-unchanged-25-price-target-on-multiple-oncology-catalysts-and-mcrpc-upside-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ORIC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656302166","title":"Oric Pharmaceuticals: Q2 Net Loss Per Share $0.38","url":"https://stock-news.laohu8.com/highlight/detail?id=2656302166","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656302166?lang=en_us&edition=fundamental","pubTime":"2026-08-04 04:59","pubTimestamp":1785790752,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260803:nPLXLM4967:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ORIC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656302187","title":"ORIC Pharmaceuticals Q2 EPS $(0.38) Misses $(0.36) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2656302187","media":"Benzinga Earnings","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656302187?lang=en_us&edition=fundamental","pubTime":"2026-08-04 04:57","pubTimestamp":1785790664,"startTime":"0","endTime":"0","summary":"ORIC Pharmaceuticals (NASDAQ:ORIC) reported quarterly losses of $(0.38) per share which missed the analyst consensus estimate of $(0.36) by 5.56 percent. This is a 19.15 percent increase over losses of $(0.47) per share","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/08/60892053/oric-pharmaceuticals-q2-eps-0-38-misses-0-36-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"ORIC Pharmaceuticals Q2 EPS $(0.38) Misses $(0.36) Estimate","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ORIC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656030469","title":"Oric Pharmaceuticals Initiates Himalayas-1 Phase 3 Trial of Rinzimetostat Plus Darolutamide in mCRPC","url":"https://stock-news.laohu8.com/highlight/detail?id=2656030469","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656030469?lang=en_us&edition=fundamental","pubTime":"2026-08-04 04:23","pubTimestamp":1785788625,"startTime":"0","endTime":"0","summary":"Oric Pharmaceuticals initiates Himalayas-1 Phase 3 trial of rinzimetostat plus darolutamide in mCRPCOric Pharmaceuticals initiated Himalayas-1, a global Phase 3 registrational trial of rinzimetostat i","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260803:nNDL3yGXwG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ORIC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656078673","title":"ORIC® Pharmaceuticals Reports Second Quarter 2026 Financial Results and Operational Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2656078673","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656078673?lang=en_us&edition=fundamental","pubTime":"2026-08-04 04:05","pubTimestamp":1785787500,"startTime":"0","endTime":"0","summary":"Initiated Himalayas-1 global Phase 3 trial in patients with mCRPC previously treated with abiraterone Entered into a clinical trial collaboration and supply agreement with Bayer to provide darolutamid","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/03/3337877/0/en/ORIC-Pharmaceuticals-Reports-Second-Quarter-2026-Financial-Results-and-Operational-Updates.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MEDX","GDOC","BK4139","NVIB","AR","IDNA","HYLG","ORIC","BK4213","LNGX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655381385","title":"Oric Pharmaceuticals Expands 2022 Inducement Equity Plan Share Pool by 1,100,000 Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2655381385","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655381385?lang=en_us&edition=fundamental","pubTime":"2026-07-31 05:20","pubTimestamp":1785446421,"startTime":"0","endTime":"0","summary":"Oric Pharmaceuticals expands 2022 inducement equity plan share pool by 1,100,000 sharesOric Pharmaceuticals adopted an amended and restated 2022 Inducement Equity Incentive Plan effective July 28, 202","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260730:nNDL1bb75b:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ORIC","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655880981","title":"Oric Pharma Director Richard A. Heyman Disposes of 13,100 Common Shares Worth $157,462.00","url":"https://stock-news.laohu8.com/highlight/detail?id=2655880981","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655880981?lang=en_us&edition=fundamental","pubTime":"2026-07-29 04:16","pubTimestamp":1785269766,"startTime":"0","endTime":"0","summary":"Oric Pharma director Richard A. Heyman disposes of 13,100 common shares worth $157,462.00Oric Pharmaceuticals director Richard A. Heyman sold 13,100 shares on July 24 at USD 12.02.He exercised options","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260728:nNDL539f3w:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Oric Pharma Director Richard A. Heyman Disposes of 13,100 Common Shares Worth $157,462.00","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ORIC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652156602","title":"ORIC® Pharmaceuticals Announces Three Presentations at the European Society for Medical Oncology (ESMO) Congress 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2652156602","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652156602?lang=en_us&edition=fundamental","pubTime":"2026-07-20 20:30","pubTimestamp":1784550600,"startTime":"0","endTime":"0","summary":"Enozertinib poster presentation to highlight data from an ongoing Phase 1b trial in first-line EGFR atypical NSCLC Rinzimetostat trial-in-progress poster presentation to highlight the ongoing Himalaya","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/07/20/3329711/0/en/ORIC-Pharmaceuticals-Announces-Three-Presentations-at-the-European-Society-for-Medical-Oncology-ESMO-Congress-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ORIC","EPV","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651891994","title":"Corrected-oric Pharmaceuticals: ‍entered Clinical Trial Collaboration and Supply Agreement with Bayer to Provide Darolutamide for Himalayas-1 (not 'oric Pharmaceuticals Inc: Proposed Deal For')","url":"https://stock-news.laohu8.com/highlight/detail?id=2651891994","media":"THOMSON REUTERS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651891994?lang=en_us&edition=fundamental","pubTime":"2026-07-15 04:20","pubTimestamp":1784060448,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260714:nL8N43G2HA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ORIC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651534489","title":"Oric Pharmaceuticals Signs Trial Collaboration with Bayer for Nubeqa Supply in Phase 3 Prostate Cancer Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2651534489","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651534489?lang=en_us&edition=fundamental","pubTime":"2026-07-15 04:07","pubTimestamp":1784059625,"startTime":"0","endTime":"0","summary":"Oric Pharmaceuticals signs trial collaboration with Bayer for Nubeqa supply in Phase 3 prostate cancer studyOric Pharmaceuticals entered a clinical trial collaboration and supply agreement with Bayer ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260714:nNDL2K3dKy:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BCDF","IE00BN0W2T93.GBP","SG9999014039.USD","NDAQ","SG9999014021.USD","ORIC","IE00BKPKM429.USD","LU2210149790.SGD","BK4139","IE00BN0W2V16.EUR","BK4112","IE00BGHQF748.EUR","IE00B64PRP62.GBP","BK4588","IE00B3QW5Z07.USD","SG9999014005.SGD","LU2210150020.SGD","LU0314104364.USD","LU2095319765.USD","IE00BN0W2W23.USD","SG9999014013.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651848989","title":"Oric® Pharmaceuticals Announces Initiation of Himalayas-1 Phase 3 Trial in Mcrpc Evaluating Rinzimetostat in Combination with Nubeqa® (darolutamide), Supported by Clinical Collaboration with Bayer","url":"https://stock-news.laohu8.com/highlight/detail?id=2651848989","media":"THOMSON REUTERS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651848989?lang=en_us&edition=fundamental","pubTime":"2026-07-15 04:05","pubTimestamp":1784059502,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260714:nTUA8JCRZM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ORIC","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651748933","title":"Oric Pharmaceuticals Inc: Proposed Deal For","url":"https://stock-news.laohu8.com/highlight/detail?id=2651748933","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651748933?lang=en_us&edition=fundamental","pubTime":"2026-07-15 04:05","pubTimestamp":1784059502,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260714:nTUA8JCRZM:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ORIC","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650916599","title":"Oric Pharmaceuticals Director Richard A. Heyman Sells 300 Shares for $3,600","url":"https://stock-news.laohu8.com/highlight/detail?id=2650916599","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650916599?lang=en_us&edition=fundamental","pubTime":"2026-07-09 04:36","pubTimestamp":1783542967,"startTime":"0","endTime":"0","summary":"Oric Pharmaceuticals director Richard A. Heyman sells 300 shares for $3,600Oric Pharmaceuticals director Richard A. Heyman disposed of 300 common shares on July 6 at $12.Indirect common stock holdings","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260708:nNDL7HL6Fs:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Oric Pharmaceuticals Director Richard A. Heyman Sells 300 Shares for $3,600","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ORIC","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648636544","title":"ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2648636544","media":"GlobeNewswire","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648636544?lang=en_us&edition=fundamental","pubTime":"2026-07-03 04:30","pubTimestamp":1783024200,"startTime":"0","endTime":"0","summary":"SOUTH SAN FRANCISCO and SAN DIEGO, July  02, 2026  (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechani","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/07/02/3321570/0/en/ORIC-Pharmaceuticals-Reports-Inducement-Grants-under-Nasdaq-Listing-Rule-5635-c-4.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ORIC","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645831890","title":"Analysts Offer Insights on Healthcare Companies: Oric Pharmaceuticals (ORIC), Biomea Fusion (BMEA) and Senseonics Holdings (SENS)","url":"https://stock-news.laohu8.com/highlight/detail?id=2645831890","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645831890?lang=en_us&edition=fundamental","pubTime":"2026-06-24 19:30","pubTimestamp":1782300628,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Oric Pharmaceuticals (ORIC), Biomea Fusion (BMEA) an...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-oric-pharmaceuticals-oric-biomea-fusion-bmea-and-senseonics-holdings-sens-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-oric-pharmaceuticals-oric-biomea-fusion-bmea-and-senseonics-holdings-sens-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","XBI","BMEA","BK4139","BK4539","BK4585","LABU","BK4581","XLV","HCSG","BK4137","LU0128526141.USD","SENS","BK4082","LU0029874061.USD","ORIC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645008853","title":"Oric Shareholders Approve Equity Plan, Governance Measures","url":"https://stock-news.laohu8.com/highlight/detail?id=2645008853","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645008853?lang=en_us&edition=fundamental","pubTime":"2026-06-23 05:00","pubTimestamp":1782162059,"startTime":"0","endTime":"0","summary":"Oric Pharmaceuticals ( ($ORIC) ) just unveiled an announcement. On June 18, 2026, ORIC Pharmaceuticals’ shareholders approved an amended and restat...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/oric-shareholders-approve-equity-plan-governance-measures?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/oric-shareholders-approve-equity-plan-governance-measures?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4215","EQR","BK4585","BK4588","ORIC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645771070","title":"Oric Pharmaceuticals shareholders approve amended, restated 2020 equity incentive plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2645771070","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645771070?lang=en_us&edition=fundamental","pubTime":"2026-06-23 04:06","pubTimestamp":1782158767,"startTime":"0","endTime":"0","summary":"Oric Pharmaceuticals held its annual shareholder meeting on June 18, 2026.Holders backed an annual cadence for future advisory votes on executive pay.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oric Pharmaceuticals Inc published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 22, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260622:nNDLlPCKL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ORIC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642262069","title":"Oric Pharmaceuticals Inc : Stifel Resumes Coverage With Buy Rating; Target Price $14","url":"https://stock-news.laohu8.com/highlight/detail?id=2642262069","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642262069?lang=en_us&edition=fundamental","pubTime":"2026-06-12 18:55","pubTimestamp":1781261730,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260612:nFWN42K01A:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ORIC"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.oricpharma.com","stockEarnings":[{"period":"1week","weight":0.1108},{"period":"1month","weight":0.1884},{"period":"3month","weight":0.461},{"period":"6month","weight":0.2409},{"period":"1year","weight":0.3087},{"period":"ytd","weight":0.5807}],"compareEarnings":[{"period":"1week","weight":0.0362},{"period":"1month","weight":0.0279},{"period":"3month","weight":0.0419},{"period":"6month","weight":0.1129},{"period":"1year","weight":0.2146},{"period":"ytd","weight":0.1271}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers. Its lead product candidate is ORIC-101, a small molecule antagonist of the glucocorticoid receptor, which has been linked to resistance to multiple classes of cancer therapeutics across various solid tumors. The company's second product candidate is ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens. It is also developing multiple precision medicines targeting other cancer resistance mechanisms. The company was founded in 2014 and is headquartered in South San Francisco, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.039993},{"month":2,"riseRate":0.5,"avgChangeRate":-0.014475},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.092137},{"month":4,"riseRate":0.166667,"avgChangeRate":-0.173514},{"month":5,"riseRate":0.571429,"avgChangeRate":0.047029},{"month":6,"riseRate":0.714286,"avgChangeRate":0.161131},{"month":7,"riseRate":0.428571,"avgChangeRate":0.002728},{"month":8,"riseRate":0.714286,"avgChangeRate":0.101711},{"month":9,"riseRate":0.166667,"avgChangeRate":-0.048915},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.0811},{"month":11,"riseRate":0.666667,"avgChangeRate":0.167402},{"month":12,"riseRate":0.5,"avgChangeRate":0.06155}],"exchange":"NASDAQ","name":"Oric Pharmaceuticals Inc.","nameEN":"Oric Pharmaceuticals Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Oric Pharmaceuticals Inc.(ORIC),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Oric Pharmaceuticals Inc.(ORIC) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Oric Pharmaceuticals Inc.,ORIC,Oric Pharmaceuticals Inc.股票,Oric Pharmaceuticals Inc.股票老虎,Oric Pharmaceuticals Inc.股票老虎国际,Oric Pharmaceuticals Inc.行情,Oric Pharmaceuticals Inc.股票行情,Oric Pharmaceuticals Inc.股价,Oric Pharmaceuticals Inc.股市,Oric Pharmaceuticals Inc.股票价格,Oric Pharmaceuticals Inc.股票交易,Oric Pharmaceuticals Inc.股票购买,Oric Pharmaceuticals Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Oric Pharmaceuticals Inc.(ORIC),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Oric Pharmaceuticals Inc.(ORIC) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction